Skip to main content
Fig. 1 | Breast Cancer Research

Fig. 1

From: KLF4 defines the efficacy of the epidermal growth factor receptor inhibitor, erlotinib, in triple-negative breast cancer cells by repressing the EGFR gene

Fig. 1

KLF4 represses migration, invasion, and long-term cell growth of breast epithelial cells. a Western blot analysis and quantitation of KLF4 expression across eight different breast cell lines: MCF10A (10A), MCF-7, T47D, SKBR3, SUM159, HCC70, MDA-MB-468 (468), and MDA-MB-231 (231). b RT-qPCR analysis of KLF4 expression levels in MDA-MB-231 and MDA-MB-468 cell lines 3 days after infection with AdGFP (AdG) or AdKLF4 (AdK). c Western blot analysis and quantitation showing KLF4 expression in MDA-MB-231 and MDA-MB-468 following infection with AdGFP (G) or AdKLF4 (K) and compared to endogenous levels in MCF-10A cells. Two biological replicates were performed. Cells were infected with AdG or AdK for 2 days and then allowed to d migrate for 6 h or e invade into Matrigel for 24 h before they were stained and counted. f MDA-MB-231 and MDA-468 cells were infected with AdG or AdK and plated. After 24 h, they were counted using trypan blue exclusion. g RT-qPCR and h western blot analysis of the KLF4 expression in MCF10A cells 3 days post-infection with a non-targeting siRNA (siNS) or siRNA targeting KLF4 (siKLF4). Cells were infected with siNS or siKLF4 and allowed to i migrate for 6 h or j invade for 24 h before they were stained and counted. Cells were k, l infected with AdG or AdK or m transfected with siNS or siKLF4, and the cell number was counted at days 3–5 using trypan blue exclusion assay. Relative values were normalized versus the control, and error bars represent the standard deviation. Experiments were performed three independent times and in triplicate with *p < 0.05

Back to article page